Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Eton Pharmaceuticals (NASDAQ: ETON), a pharmaceutical company specializing in rare disease treatments, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results.
Management will take live questions during the call and will also address emailed questions from investors sent to investorrelations@etonpharma.com. The webcast will be accessible through Eton's investor relations website and will remain available for 30 days after the event.
Eton Pharmaceuticals (NASDAQ: ETON), un'azienda farmaceutica specializzata in trattamenti per malattie rare, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 13 maggio 2025. La società terrà una conference call e una trasmissione audio in webcast alle 16:30 ET (15:30 CT) per discutere i risultati.
Il management risponderà a domande in diretta durante la chiamata e affronterà anche le domande inviate via email dagli investitori all'indirizzo investorrelations@etonpharma.com. Il webcast sarà accessibile tramite il sito web delle relazioni con gli investitori di Eton e resterà disponibile per 30 giorni dopo l'evento.
Eton Pharmaceuticals (NASDAQ: ETON), una compañía farmacéutica especializada en tratamientos para enfermedades raras, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 13 de mayo de 2025. La empresa realizará una llamada en conferencia y una transmisión de audio por webcast a las 4:30 p.m. ET (3:30 p.m. CT) para discutir los resultados.
La dirección responderá preguntas en vivo durante la llamada y también atenderá preguntas enviadas por correo electrónico por los inversores a investorrelations@etonpharma.com. El webcast estará disponible a través del sitio web de relaciones con inversores de Eton y permanecerá accesible durante 30 días después del evento.
Eton Pharmaceuticals (NASDAQ: ETON)는 희귀 질환 치료에 특화된 제약 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 13일 화요일에 예정하고 있습니다. 회사는 오후 4시 30분 ET (오후 3시 30분 CT)에 컨퍼런스 콜과 오디오 웹캐스트를 통해 실적을 논의할 예정입니다.
경영진은 통화 중 실시간 질문을 받고, 투자자들이 investorrelations@etonpharma.com으로 보낸 이메일 질문도 답변할 예정입니다. 웹캐스트는 Eton의 투자자 관계 웹사이트에서 접속 가능하며, 행사 후 30일간 시청할 수 있습니다.
Eton Pharmaceuticals (NASDAQ : ETON), une société pharmaceutique spécialisée dans les traitements des maladies rares, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mardi 13 mai 2025. L'entreprise organisera une conférence téléphonique et une diffusion audio en webcast à 16h30 ET (15h30 CT) pour discuter des résultats.
La direction répondra aux questions en direct pendant l'appel et prendra également en compte les questions envoyées par e-mail par les investisseurs à investorrelations@etonpharma.com. Le webcast sera accessible via le site des relations investisseurs d'Eton et restera disponible pendant 30 jours après l'événement.
Eton Pharmaceuticals (NASDAQ: ETON), ein Pharmaunternehmen, das sich auf die Behandlung seltener Krankheiten spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 13. Mai 2025 geplant. Das Unternehmen wird eine Telefonkonferenz und eine Audio-Webcast um 16:30 Uhr ET (15:30 Uhr CT) abhalten, um die Ergebnisse zu besprechen.
Das Management wird während des Anrufs live Fragen beantworten und auch per E-Mail an investorrelations@etonpharma.com eingereichte Fragen von Investoren behandeln. Der Webcast wird über die Investor-Relations-Website von Eton zugänglich sein und für 30 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Dial In* (Audio Only) Click Here
Webcast: Click Here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
When will Eton Pharmaceuticals (ETON) report Q1 2025 earnings?
How can investors participate in Eton Pharmaceuticals' Q1 2025 earnings call?
Where can I access the replay of Eton Pharmaceuticals' Q1 2025 earnings webcast?
What is Eton Pharmaceuticals' main business focus?
